ACHE and Alzheimer disease: SAI levels are significantly reduced by scopolamine, a muscarinic cholinergic antagonist, in young healthy adults (Di Lazzaro et al., 2000) and can be improved with acetylcholinesterase inhibitors in patients with AD (Di Lazzaro et al., 2002).